The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.
Health Professionals
Gene Expression Profile Testing Offers Clinicians a Path to Safely Avoid SLNB in Low-Risk Melanoma Patients
New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.
Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape
On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape.
Innovative Radiolabeled Antibody Shows Promise in Cancer Diagnosis and Therapy
A newly created radiolabeled antibody targeting the cancer-associated antigen IL13R?2 has demonstrated remarkable specificity in binding to cancer cells, while sparing healthy tissues. This advancement, tested across various cancer types, shows promise for enhancing tumor detection and treatment through radioimmunotherapy.